Citadel Advisors
SPRO icon

Citadel Advisors’s Spero Therapeutics SPRO Stock Holding History

Citadel Advisors’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-26,700
Closed -$62.5K – 14783
2026
Q1 		$62.5K Buy
+26,700
New +$63.4K ﹤0.01% 12307
2025
Q2 		– Sell
-9,300
Closed -$6.7K – 14931
2025
Q1 		$6.7K Buy
9,300
+9,100
+4,550% +$7.68K ﹤0.01% 13735
2024
Q4 		$206 Hold
200
– – ﹤0.01% 14366
2024
Q3 		$268 Sell
200
-300
-60% -$402 ﹤0.01% 14062
2024
Q2 		$650 Buy
+500
New +$754 ﹤0.01% 13942
2023
Q3 		– Sell
-100
Closed -$145 – 15062
2023
Q2 		$145 Buy
+100
New +$171 ﹤0.01% 14205
2022
Q3 		– Sell
-40,800
Closed -$30K – 13552
2022
Q2 		$30K Buy
40,800
+24,000
+143% +$69.8K ﹤0.01% 12228
2022
Q1 		$146K Buy
16,800
+1,200
+8% +$12.3K ﹤0.01% 11879
2021
Q4 		$250K Sell
15,600
-17,800
-53% -$283K ﹤0.01% 11355
2021
Q3 		$615K Sell
33,400
-4,900
-13% -$78.6K ﹤0.01% 9375
2021
Q2 		$535K Buy
38,300
+7,300
+24% +$102K ﹤0.01% 9918
2021
Q1 		$456K Sell
31,000
-300
-1% -$5.28K ﹤0.01% 9870
2020
Q4 		$607K Buy
31,300
+15,300
+96% +$239K ﹤0.01% 7791
2020
Q3 		$179K Buy
+16,000
New +$189K ﹤0.01% 8896

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's SPRO Position: Q2 2026 in Review

Citadel Advisors sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 376,458 shares — an estimated $985K sold.

Citadel Advisors first reported a position in SPRO in Q3 2020 and held it in 15 quarters. The position peaked at $927K in Q4 2025. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Citadel Advisors reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 376,458 Spero Therapeutics shares in Q2 2026, an estimated $985K.
  • Citadel Advisors first reported a position in Spero Therapeutics in Q3 2020 and held it in 15 quarters.
  • Citadel Advisors's Spero Therapeutics position peaked at $927K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.